Cargando…
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
BACKGROUND: Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived CD200 and its receptor on myeloid cells. We suggest that CD200/CD200R interactions on m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296547/ https://www.ncbi.nlm.nih.gov/pubmed/25598973 http://dx.doi.org/10.1186/s40425-014-0046-9 |
_version_ | 1782353006354759680 |
---|---|
author | Moertel, Christopher L Xia, Junzhe LaRue, Rebecca Waldron, Nate N Andersen, Brian M Prins, Robert M Okada, Hideho Donson, Andrew M Foreman, Nicholas K Hunt, Matthew A Pennell, Christopher A Olin, Michael R |
author_facet | Moertel, Christopher L Xia, Junzhe LaRue, Rebecca Waldron, Nate N Andersen, Brian M Prins, Robert M Okada, Hideho Donson, Andrew M Foreman, Nicholas K Hunt, Matthew A Pennell, Christopher A Olin, Michael R |
author_sort | Moertel, Christopher L |
collection | PubMed |
description | BACKGROUND: Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived CD200 and its receptor on myeloid cells. We suggest that CD200/CD200R interactions on myeloid cells expand the myeloid-derived suppressor cell (MDSC) population and that blocking tumor-derived CD200 will enhance the efficacy of immunotherapy. METHODS: CD200 mRNA expression levels in human brain tumor tissue samples were measured by microarray. The amount of circulating CD200 protein in the sera of patients with brain tumors was determined by ELISA and, when corresponding peripheral blood samples were available, was correlated quantitatively with MDSCs. CD200-derived peptides were used as competitive inhibitors in a mouse model of glioblastoma immunotherapy. RESULTS: CD200 mRNA levels were measured in human brain tumors, with different expression levels being noted among the sub groups of glioblastoma, medulloblastoma and ependymoma. Serum CD200 concentrations were highest in patients with glioblastoma and correlated significantly with MDSC expansion. Similarly, in vitro studies determined that GL261 cells significantly expanded a MDSC population. Interestingly, a CD200R antagonist inhibited the expansion of murine MDSCs in vitro and in vivo. Moreover, inclusion of CD200R antagonist peptide in glioma tumor lysate-derived vaccines slowed tumor growth and significantly enhanced survival. CONCLUSION: These data suggest that CNS-derived tumors can evade immune surveillance by engaging CD200. Because of the homology between mouse and human CD200, our data also suggest that blockade of CD200 binding to its receptor will enhance the efficacy of immune mediated anti-tumor strategies for brain tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-014-0046-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4296547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42965472015-01-17 CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy Moertel, Christopher L Xia, Junzhe LaRue, Rebecca Waldron, Nate N Andersen, Brian M Prins, Robert M Okada, Hideho Donson, Andrew M Foreman, Nicholas K Hunt, Matthew A Pennell, Christopher A Olin, Michael R J Immunother Cancer Research Article BACKGROUND: Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived CD200 and its receptor on myeloid cells. We suggest that CD200/CD200R interactions on myeloid cells expand the myeloid-derived suppressor cell (MDSC) population and that blocking tumor-derived CD200 will enhance the efficacy of immunotherapy. METHODS: CD200 mRNA expression levels in human brain tumor tissue samples were measured by microarray. The amount of circulating CD200 protein in the sera of patients with brain tumors was determined by ELISA and, when corresponding peripheral blood samples were available, was correlated quantitatively with MDSCs. CD200-derived peptides were used as competitive inhibitors in a mouse model of glioblastoma immunotherapy. RESULTS: CD200 mRNA levels were measured in human brain tumors, with different expression levels being noted among the sub groups of glioblastoma, medulloblastoma and ependymoma. Serum CD200 concentrations were highest in patients with glioblastoma and correlated significantly with MDSC expansion. Similarly, in vitro studies determined that GL261 cells significantly expanded a MDSC population. Interestingly, a CD200R antagonist inhibited the expansion of murine MDSCs in vitro and in vivo. Moreover, inclusion of CD200R antagonist peptide in glioma tumor lysate-derived vaccines slowed tumor growth and significantly enhanced survival. CONCLUSION: These data suggest that CNS-derived tumors can evade immune surveillance by engaging CD200. Because of the homology between mouse and human CD200, our data also suggest that blockade of CD200 binding to its receptor will enhance the efficacy of immune mediated anti-tumor strategies for brain tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-014-0046-9) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-16 /pmc/articles/PMC4296547/ /pubmed/25598973 http://dx.doi.org/10.1186/s40425-014-0046-9 Text en © Moertel et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Moertel, Christopher L Xia, Junzhe LaRue, Rebecca Waldron, Nate N Andersen, Brian M Prins, Robert M Okada, Hideho Donson, Andrew M Foreman, Nicholas K Hunt, Matthew A Pennell, Christopher A Olin, Michael R CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title_full | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title_fullStr | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title_full_unstemmed | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title_short | CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy |
title_sort | cd200 in cns tumor-induced immunosuppression: the role for cd200 pathway blockade in targeted immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296547/ https://www.ncbi.nlm.nih.gov/pubmed/25598973 http://dx.doi.org/10.1186/s40425-014-0046-9 |
work_keys_str_mv | AT moertelchristopherl cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT xiajunzhe cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT laruerebecca cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT waldronnaten cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT andersenbrianm cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT prinsrobertm cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT okadahideho cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT donsonandrewm cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT foremannicholask cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT huntmatthewa cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT pennellchristophera cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy AT olinmichaelr cd200incnstumorinducedimmunosuppressiontheroleforcd200pathwayblockadeintargetedimmunotherapy |